Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 1/2017

01-02-2017

Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review

Authors: Eleni Tiniakou, Andrew L. Mammen

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2017

Login to get access

Abstract

The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases (collectively known as myositis) affecting the skeletal muscles as well as other organ systems such as skin, lungs, and joints. The primary forms of myositis include polymyositis (PM), dermatomyositis (PM), and immune-mediated necrotizing myopathy (IMNM). Patients with these diseases experience progressive proximal muscle weakness, have characteristic muscle biopsy findings, and produce autoantibodies that are associated with unique clinical features. One distinguishing feature of these patients is that they are also known to have an increased risk of cancer. Since the first description of the association in 1916, it has been extensively reported in the medical literature. However, there have been significant variations between the different studies with regard to the degree of cancer risk in patients with IIM. These discrepancies can, in part, be attributed to differences in the definition of malignancy-associated myositis used in different studies. In recent years, significant advances have been made in defining specific features of IIM that are associated with the development of malignancy. One of these has been myositis-specific antibodies (MSAs), which are linked to distinct clinical phenotypes and categorize patients into groups with more homogeneous features. Indeed, patients with certain MSAs seem to be at particularly increased risk of malignancy. This review attempts a systematic evaluation of research regarding the association between malignancy and myositis.
Literature
1.
Mammen AL (2010) Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 1184:134–53PubMedCrossRef
2.
Rider LG, Miller FW (2011) Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 305(2):183–90PubMedPubMedCentralCrossRef
3.
Sterz G (1916) Polymyositis. Berl Klin Wochenschr 53:489
4.
Kankelheit H (1916) Uber primare nichteitrige Polymyositis. Dtsch Arch Klin Med 120:335–49
5.
Troyanov Y et al (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84(4):231–49CrossRef
6.
Love LA et al (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70(6):360–74CrossRef
7.
Chinoy H et al (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66(10):1345–9PubMedPubMedCentralCrossRef
8.
9.
Gunawardena H, Betteridge ZE, McHugh NJ (2009) Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 48(6):607–12CrossRef
10.
Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–7PubMedCrossRef
11.
12.
13.
Limaye V et al (2013) The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 33(4):965–71PubMedCrossRef
14.
Airio A, Pukkala E, Isomaki H (1995) Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22(7):1300–3PubMed
15.
So MW et al (2011) Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol 38(11):2432–5PubMedCrossRef
16.
Antiochos BB et al (2009) Malignancy is associated with dermatomyositis but not polymyositis in Northern New England. USA J Rheumatol 36(12):2704–10PubMedCrossRef
17.
Yang Z et al (2015) Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 42(2):282–91PubMedCrossRef
18.
Sigurgeirsson B et al (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326(6):363–7PubMedCrossRef
19.
Chow WH et al (1995) Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 6(1):9–13PubMedCrossRef
20.
Stockton D, Doherty VR, Brewster DH (2001) Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85(1):41–5PubMedPubMedCentralCrossRef
21.
Miller FW et al (2003) Diagnostic criteria for polymyositis and dermatomyositis. Lancet 362(9397):1762–3, author reply 1763 PubMedCrossRef
22.
23.
Buchbinder R et al (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134(12):1087–95PubMedCrossRef
24.
Buchbinder R, Hill CL (2002) Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 4(5):415–26PubMedCrossRef
25.
26.
Maoz CR et al (1998) High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 27(5):319–24PubMedCrossRef
27.
Andras C et al (2008) Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35(3):438–44PubMed
28.
Hill CL et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250):96–100PubMedCrossRef
29.
Ungprasert P et al (2013) Clinical features of inflammatory myopathies and their association with malignancy: a systematic review in asian population. ISRN Rheumatol 2013:509354PubMedPubMedCentralCrossRef
30.
Marie I et al (2012) Hematological malignancy associated with polymyositis and dermatomyositis. Autoimmun Rev 11(9):615–20PubMedCrossRef
31.
Mebazaa A et al (2011) Dermatomyositis and breast cancer: a multicenter Tunisian retrospective study of 13 cases. Tunis Med 89(1):18–22PubMed
32.
Mordel N et al (1988) Concurrence of ovarian cancer and dermatomyositis. A report of two cases and literature review. J Reprod Med 33(7):649–55PubMed
33.
Wang J et al (2013) Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol 169(4):838–47PubMedCrossRef
34.
Gallais V, Crickx B, Belaich S (1996) Prognostic factors and predictive signs of malignancy in adult dermatomyositis. Ann Dermatol Venereol 123(11):722–6PubMed
35.
Basset-Seguin N et al (1990) Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol 126(5):633–7PubMedCrossRef
36.
Prohic A et al (2009) Clinical and biological factors predictive of malignancy in dermatomyositis. J Eur Acad Dermatol Venereol 23(5):591–2PubMedCrossRef
37.
Fardet L et al (2010) Frequency, clinical features and prognosis of cutaneous manifestations in adult patients with reactive haemophagocytic syndrome. Br J Dermatol 162(3):547–53PubMedCrossRef
38.
Feldman D et al (1983) Cutaneous vasculitis in adult polymyositis/dermatomyositis. J Rheumatol 10(1):85–9PubMed
39.
Hunger RE, Durr C, Brand CU (2001) Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology 202(2):123–6PubMedCrossRef
40.
Fain O et al (2007) Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 57(8):1473–80PubMedCrossRef
41.
Lu X et al (2014) Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One 9(4):e94128PubMedPubMedCentralCrossRef
42.
Ponyi A et al (2005) Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 1051:64–71PubMedCrossRef
43.
44.
Uchino M et al (2013) Muscle biopsy findings predictive of malignancy in rare infiltrative dermatomyositis. Clin Neurol Neurosurg 115(5):603–6PubMedCrossRef
45.
46.
Abrahamova J, Majsky A, Koutecky J (1981) HLA-antigens in germ cell tumors of various sites. Onkologie 4(1):19–20PubMed
47.
Hornmark-Stenstam B, Landberg T, Low B (1978) HLA antigens in Hodgkin's disease of very long survival. Acta Radiol Oncol Radiat Phys Biol 17(4):283–8PubMedCrossRef
48.
Yang Y et al (2001) Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 21(3):106–11PubMedCrossRef
49.
Rose C et al (1994) Predictive signs of cancers in dermatomyositis. Study of 29 cases. Rev Med Interne 15(1):19–24PubMedCrossRef
50.
Park J et al (2001) Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 17(6):1216–9PubMedCrossRef
51.
Li J et al (2014) Idiopathic pulmonary fibrosis will increase the risk of lung cancer. Chin Med J (Engl) 127(17):3142–9
52.
Hubbard R et al (2000) Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 161(1):5–8PubMedCrossRef
53.
54.
Castaneda-Pomeda M, Prieto-Gonzalez S, Grau JM (2011) Antisynthetase syndrome and malignancy: our experience. J Clin Rheumatol 17(8):458PubMedCrossRef
55.
Marie I et al (2012) Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 11(10):739–45PubMedCrossRef
56.
Neri R et al (2014) Cancer-associated myositis: a 35-year retrospective study of a monocentric cohort. Rheumatol Int 34(4):565–9PubMedCrossRef
57.
Legault D et al (2008) Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J Rheumatol 35(1):169–71PubMed
58.
Watkins J et al (2004) Jo-1 syndrome with associated poorly differentiated adenocarcinoma. Rheumatology (Oxford) 43(3):389–90CrossRef
59.
Gunawardena H et al (2009) Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 60(6):1807–14PubMedPubMedCentralCrossRef
60.
Espada G et al (2009) Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 36(11):2547–51PubMedCrossRef
61.
Ichimura Y et al (2012) Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71(5):710–3PubMedCrossRef
62.
Bodoki L et al (2014) Four dermatomyositis-specific autoantibodies-anti-TIF1gamma, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 13(12):1211–9PubMedCrossRef
63.
Ceribelli A et al (2012) Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 14(2):R97PubMedPubMedCentralCrossRef
64.
65.
Fiorentino DF et al (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 65(11):2954–62PubMedPubMedCentralCrossRef
66.
Targoff IN et al (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54(11):3682–9PubMedCrossRef
67.
Kaji K et al (2007) Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46(1):25–8CrossRef
68.
Targoff IN et al (2006) Autoantibodies to transcriptional intermediary factor 1-garnma (TIF1-g) in dermatomyositis. Arthritis Rheum 54(9):S518–S518
69.
Fujimoto M et al (2012) Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64(2):513–522PubMedCrossRef
70.
Ohashi M et al (2011) Anti-p155/140 antibody-positive dermatomyositis with metastasis originating from an unknown site. Acta Derm Venereol 91(1):84–5PubMedCrossRef
71.
Hoshino K et al (2010) Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 49(9):1726–33CrossRef
72.
Fujikawa K et al (2009) Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol 38(4):263–267PubMedCrossRef
73.
Trallero-Araguas E et al (2012) Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: A systematic review and meta-analysis. Arthritis Rheum 64(2):523–532PubMedCrossRef
74.
Christopher-Stine L et al (2010) A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62(9):2757–66PubMedPubMedCentralCrossRef
75.
Mammen AL et al (2011) Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63(3):713–21PubMedPubMedCentralCrossRef
76.
. Limaye V, et al. (2014) Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve,
77.
Pari Basharat AL, Andrew L Mammen, Iago Pinal-Fernandez, Tanmayee Bichile, Thomas E Lloyd, Sonye K. Danoff, Livia Casciola-Rosen and Lisa Christopher-Stine, Diabetes and Atorvastatin Are Potential Risk Factors for Statin-Associated Myopathy with Autoantibodies Against 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase, in American College of Rheumatology Meeting2014: Boston, USA
78.
Yves Allenbach, J.K., Nicolas Champtiax, Aurelie Grados, Yoland Schoindre, Aude Rigolet, Kuberaka Mariampillai, Lucil Musset, Baptiste Hervier, Olivier Benveniste (2015) Cancer and necrotizing immune myopathy: high incidence in anti-HMGCR positive and seronegative patients but not in anti-SRP positive patients, in First international conference on myositis2015: Stockholm, Sweden.
79.
Yoshimura N et al (1988) A case of chronic myositis associated with rimmed vacuole formation and hepatocellular carcinoma--on the entity of inclusion body myositis. Rinsho Shinkeigaku 28(1):55–61PubMed
80.
Alexandrescu DT et al (2005) Steroid-responsive inclusion body myositis associated with endometrial cancer. Clin Exp Rheumatol 23(1):93–6PubMed
81.
Talanin NY et al (1999) Dermatomyositis with the features of inclusion body myositis associated with carcinoma of the bladder. Br J Dermatol 141(5):926–30PubMedCrossRef
82.
Jensen ML et al (1997) Inclusion body myositis and transitional cell carcinoma of the bladder: significant resolution of symptoms after tumor excision. Arch Phys Med Rehabil 78(3):327–9PubMedCrossRef
83.
Arnardottir S et al (2001) Report of a patient with inclusion body myositis and CD8+ chronic lymphocytic leukaemia--post-mortem analysis of muscle and brain. Acta Neurol Scand 103(2):131–5PubMedCrossRef
84.
85.
Wakata N et al (2002) Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 41(11):729–34PubMedCrossRef
86.
Masuda H, Urushibara M, Kihara K (2003) Successful treatment of dermatomyositis associated with adenocarcinoma of the prostate after radical prostatectomy. J Urol 169(3):1084PubMedCrossRef
87.
Yoshinaga A et al (2005) Successful cure of dermatomyositis after treatment of nonseminomatous testicular cancer. Int J Urol 12(6):593–5PubMedCrossRef
88.
Bonnetblanc JM, Bernard P, Fayol J (1990) Dermatomyositis and malignancy. A multicenter cooperative study. Dermatologica 180(4):212–6PubMedCrossRef
89.
Tallai B et al (2006) Prostate cancer underlying acute, definitive dermatomyositis: successful treatment with radical perineal prostatectomy. Clin Rheumatol 25(1):119–20PubMedCrossRef
90.
Solomon SD, Maurer KH (1983) Association of dermatomyositis and dysgerminoma in a 16-year-old patient. Arthritis Rheum 26(4):572–3PubMedCrossRef
91.
Cherin P et al (1993) Dermatomyositis and ovarian cancer: a report of 7 cases and literature review. J Rheumatol 20(11):1897–9PubMed
92.
Whitmore SE, Rosenshein NB, Provost TT (1994) Ovarian cancer in patients with dermatomyositis. Medicine (Baltimore) 73(3):153–60CrossRef
93.
Whitmore SE et al (1997) Serum CA-125 screening for ovarian cancer in patients with dermatomyositis. Gynecol Oncol 65(2):241–4PubMedCrossRef
94.
Amoura Z et al (2005) Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev 14(5):1279–82PubMedCrossRef
95.
Wong RC et al (2002) Transient elevation of the tumor markers CA 15-3 and CASA as markers of interstitial lung disease rather than underlying malignancy in dermatomyositis sine myositis. J Clin Rheumatol 8(4):204–7PubMedCrossRef
96.
Selva-O'Callaghan A et al (2010) Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med 123(6):558–62PubMedCrossRef
97.
Owada T et al (2012) Detection of inflammatory lesions by f-18 fluorodeoxyglucose positron emission tomography in patients with polymyositis and dermatomyositis. J Rheumatol 39(8):1659–65PubMedCrossRef
98.
Joseph CG et al (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343(6167):152–7PubMedCrossRef
99.
Shah AA et al (2010) Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 62(9):2787–95PubMedPubMedCentralCrossRef
100.
Le Gallo M et al (2012) Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 44(12):1310–5PubMedPubMedCentralCrossRef
101.
Casciola-Rosen L et al (2005) Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201(4):591–601PubMedPubMedCentralCrossRef
102.
103.
Levine SM (2006) Cancer and myositis: new insights into an old association. Curr Opin Rheumatol 18(6):620–4PubMedCrossRef
104.
Kasuya A et al (2013) TIF1 gamma-overexpressing, Highly Progressive Endometrial Carcinoma in a Patient with Dermatomyositis Positive for Malignancy-associated Anti-p155/140 Autoantibody. Acta Derm Venereol 93(6):715–716PubMedCrossRef
105.
Bohan A et al (1977) Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 56(4):255–86CrossRef
106.
Vesterager L, Worm AM, Thomsen K (1980) Dermatomyositis and malignancy. Clin Exp Dermatol 5(1):31–5PubMedCrossRef
107.
Callen JP et al (1980) The relationship of dermatomyositis and polymyositis to internal malignancy. Arch Dermatol 116(3):295–8PubMedCrossRef
108.
Goh CL, Rajan VS (1983) Dermatomyositis in a skin clinic. Ann Acad Med Singapore 12(1):6–12PubMed
109.
Hoffman GS et al (1983) Presentation, Treatment, and Prognosis of Idiopathic Inflammatory Muscle Disease in a Rural Hospital. Am J Med 75(3):433–438PubMedCrossRef
110.
Benbassat J et al (1985) Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum 28(3):249–55PubMedCrossRef
111.
Manchul LA et al (1985) The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. Arch Intern Med 145(10):1835–9PubMedCrossRef
112.
Tymms KE, Webb J (1985) Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 12(6):1140–8PubMed
113.
Holden DJ, Brownell AK, Fritzler MJ (1985) Clinical and serologic features of patients with polymyositis or dermatomyositis. Can Med Assoc J 132(6):649–53PubMedPubMedCentral
114.
115.
Baron M, Small P (1985) Polymyositis/dermatomyositis: clinical features and outcome in 22 patients. J Rheumatol 12(2):283–6PubMed
116.
Hochberg MC, Feldman D, Stevens MB (1986) Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 15(3):168–78PubMedCrossRef
117.
Lakhanpal S et al (1986) Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 61(8):645–53PubMedCrossRef
118.
Ponge A et al (1987) Para-Neoplastic Dermatomyositis-Polymyositis. Revue De Medecine Interne 8(3):251–256PubMedCrossRef
119.
Cox NH et al (1990) Dermatomyositis. Disease associations and an evaluation of screening investigations for malignancy. Arch Dermatol 126(1):61–5PubMedCrossRef
120.
Prasad ML et al (1992) Idiopathic inflammatory myopathy—clinicopathological observations in the Indian population. Br J Rheumatol 31(12):835–839PubMedCrossRef
121.
Koh ET et al (1993) Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 52(12):857–61PubMedPubMedCentralCrossRef
122.
Selvaag E, Thune P, Austad J (1994) Dermatomyositis and cancer. A retrospective study. Tidsskr Nor Laegeforen 114(20):2378–80PubMed
123.
Dawkins MA et al (1998) Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol 38(3):397–404PubMedCrossRef
124.
Dourmishev LA (1999) Dermatomyositis associated with malignancy. 12 case reports. Adv Exp Med Biol 455:193–9PubMedCrossRef
125.
Ang P, Sugeng MW, Chua SH (2000) Classical and amyopathic dermatomyositis seen at the National Skin Centre of Singapore: a 3-year retrospective review of their clinical characteristics and association with malignancy. Ann Acad Med Singapore 29(2):219–23PubMed
126.
Chen YJ, Wu CY, Shen JL (2001) Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 144(4):825–31PubMedCrossRef
127.
Amerio P et al (2002) Usefulness of erythrocyte sedimentation rate as tumor marker in cancer associated dermatomyositis. Eur J Dermatol 12(2):165–9PubMed
128.
Louthrenoo W et al (2002) Serum muscle enzymes, muscle pathology and clinical muscle weakness: correlation in Thai patients with polymyositis/dermatomyositis. J Med Assoc Thai 85(1):26–32PubMed
129.
Porkodi R et al (2002) Clinical spectrum of inflammatory myositis in South India--a ten year study. J Assoc Physicians India 50:1255–8PubMed
130.
Sparsa A et al (2002) Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 138(7):885–90PubMedCrossRef
131.
Mebazaa A et al (2003) Dermatomyositis and malignancy in Tunisia: a multicenter national retrospective study of 20 cases. J Am Acad Dermatol 48(4):530–4PubMedCrossRef
132.
Burnouf M et al (2003) Cutaneous necrosis is predictive of cancer in adult dermatomyositis. Ann Dermatol Venereol 130(3):313–6PubMed
133.
Kang EH et al (2005) Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 44(10):1282–6CrossRef
134.
135.
Tani K et al (2007) Comparison of clinical course of polymyositis and dermatomyositis: a follow-up study in Tokushima University Hospital. J Med Invest 54(3-4):295–302PubMedCrossRef
136.
Mustafa KN, Dahbour SS (2010) Clinical characteristics and outcomes of patients with idiopathic inflammatory myopathies from Jordan 1996-2009. Clin Rheumatol 29(12):1381–5PubMedCrossRef
137.
Kuo CF et al (2011) Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 165(6):1273–9PubMedCrossRef
138.
Azuma K et al (2011) Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 21(2):178–83PubMedCrossRef
139.
Shu XM et al (2011) Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China. BMC Neurol 11:143PubMedPubMedCentralCrossRef
140.
Teh CL, Wong JS, Soo HH (2012) Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak General Hospital. Rheumatol Int 32(1):265–8PubMedCrossRef
141.
Mok CC et al (2012) Standardized Incidence Ratios and Predictors of Malignancies in 215 Southern Chinese Patients with Inflammatory Myopathies. Arthritis Rheum 64(10):S96–S96
142.
Chen D et al (2014) Incidence and predictive factors for malignancies with dermatomyositis: a cohort from southern China. Clin Exp Rheumatol 32(5):615–21PubMed
143.
Ortigosa LC, Reis VM (2014) Dermatomyositis: analysis of 109 patients surveyed at the Hospital das Clinicas (HCFMUSP), Sao Paulo. Brazil An Bras Dermatol 89(5):719–27PubMedCrossRef
144.
Danieli MG et al (2014) Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun Rev 13(10):1048–54PubMedCrossRef
145.
Marie I et al (1999) Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 78(3):139–47CrossRef
146.
Selva-O'Callaghan A et al (2002) The neural network as a predictor of cancer in patients with inflammatory myopathies. Arthritis Rheum 46(9):2547–8PubMedCrossRef
147.
Requena C et al (2014) Paraneoplastic dermatomyositis: a study of 12 cases. Actas Dermosifiliogr 105(7):675–82PubMedCrossRef
Metadata
Title
Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review
Authors
Eleni Tiniakou
Andrew L. Mammen
Publication date
01-02-2017
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 1/2017
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-015-8511-x

Other articles of this Issue 1/2017

Clinical Reviews in Allergy & Immunology 1/2017 Go to the issue

ReviewPaper

A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy

ReviewPaper

The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review

ReviewPaper

Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms

ReviewPaper

Gorham-Stout Disease: a Clinical Case Report and Immunological Mechanisms in Bone Erosion

ReviewPaper

Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group

ReviewPaper

Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits